Abstract
The production process of in vitro transcribed messenger RNA (IVT-mRNA)-based vaccines has matured in recent years, partly due to the fight against infectious diseases such as COVID-19. One key to success has been the use of modified, next to canonical, nucleotides and the efficient addition of a Cap-structure and poly A tail to the 5’ and 3’ end, respectively, of this massive biomolecule. These important features affect mRNA stability and impact translation efficiency, consequently boosting the optimization and implementation of liquid chromatography–mass spectrometry (LC–MS)-based oligonucleotide profiling methods for their characterization. This article will provide an overview of these LC–MS methods at a fundamental and application level. It will be shown how LC–MS is implemented in mRNA-based vaccine analysis to determine the capping efficiency and the poly A tail length, and how it allows, via RNA mapping, (i) to determine the mRNA sequence, (ii) to screen the fidelity of the manufactured modifications, and (iii) to identify and quantify unwanted modifications resulting from manufacturing or storage, and sequence variants resulting from mutation or transcription errors.
Publisher
Multimedia Pharma Sciences, LLC
Reference65 articles.
1. R. Verbeke, I. Lentacker, S.C. De Smedt, and H. Dewitte, J. Control Release 333, 511–520 (2021).
2. L. Schoenmaker, D. Witzigmann, J.A. Kulkarni, R. Verbeke, G. Kersten, W. Jiskoot, and D.J.A. Crommelin, Int. J. Pharmaceutics 601, 120586 (2021).
3. J.A. Wolff, R.W. Malone, P. Williams, W. Chong, G. Ascadi, A. Jani, and P.L. Feigner, Science 247, 1465–1468 (1990).
4. R.M. Conry, A.F. LoBuglio, M. Wright, L. Sumerel, M.J. Pike, F. Johanning, R. Benjamin, D. Lu, and D.T. Curiel, Cancer Res. 55, 1397–1400 (1995).
5. J.D. Beck, D. Reidenbach, N. Salomon, U. Sahin, Ö. Türeci, M. Vormehr, and L.M. Kranz, Molecular Cancer 20, 69 (2021).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献